Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 1335

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1335

License Grant
The Licensee exclusively Licensed rights from the Licensor, to intellectual property that relate to KB001-A.

The Licensee was granted rights to practice the invention as well as further develop antibodies to treat Pa.

License Property
These intellectual property rights include a method of treatment of Pa, ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (Pa), using isolated antibodies and an antibody that specifically binds to a key target epitope, as well as diagnostic methods useful in the detection of infection by Pa.

KB001 is a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF).

IPSCIO Record ID: 28884

License Grant
Licensee regains full global rights to license, develop, manufacture and commercialize KB001-A in all indications, as well as a non-exclusive license to the KB001-A manufacturing process developed by Licensor.
License Property
The KB001-A is an investigational new biologic for the treatment and prevention of Pseudomonas aeruginosa (Pa) infections.

IPSCIO Record ID: 1334

License Grant
The Licensor signed an Agreement with the Licensee granting  exclusive worldwide rights to develop and commercialize KB001-A for all indications.
License Property
Under this Agreement, the Licensee is solely responsible for the research, development, manufacture, and commercialization of KB001-A, except that the Licensor retained responsibility for developing and commercializing the product for CF and bronchiectasis.

The Licensee is solely responsible for the costs and development of KB001-A for pneumonia prevention and other hospital indications. We are currently planning a Phase 2 trial in CF.

Field of Use
KB001-A, a Humaneeredâ„¢, anti-PcrV PEGylated Fab form of antibody that is being developed for the prevention and treatment of Pa infections in mechanically ventilated patients and chronically infected CF patients.

IPSCIO Record ID: 118195

License Grant
The parties entered into an agreement to obtain worldwide rights to TOBI.
License Property
TOBI, is an inhaled antibiotic that was developed to treat pseudomonal lung infections. TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.  TOBI also is being used by non-CF patients with similar respiratory infections.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 28236

License Grant
The company entered into a license agreement to obtain worldwide rights to TOBI with a Foundation.
License Property
The drug TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.
Field of Use
This agreement pertains to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.